Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TCRX

Tscan Therapeutics Inc

Dec 11 • 04:00PM ET

3.08

Dollar change -0.25
Percentage change -7.51	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD CRSP ALLO NTLA FATE BLUE EDIT CLLS PGEN ADAP

| Held by: VTI IWM SURI VXF VTWO IWO IWN IWC DFAS VTWG

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.94	Insider Own	18.47%	Shs Outstand	49.08M	Perf Week	-30.79%
Market Cap	164.38M	Forward P/E	-	EPS next Y	-1.28	Insider Trans	-1.49%	Shs Float	43.51M	Perf Month	-45.96%
Income	-111.30M	PEG	-	EPS next Q	-0.32	Inst Own	74.09%	Short Float	5.33%	Perf Quarter	-44.40%
Sales	9.36M	P/S	17.56	EPS this Y	6.43%	Inst Trans	-1.66%	Short Ratio	9.32	Perf Half Y	-65.32%
Book/sh	4.29	P/B	0.72	EPS next Y	-0.98%	ROA	-34.81%	Short Interest	2.32M	Perf Year	-48.32%
Cash/sh	5.08	P/C	0.61	EPS next 5Y	-	ROE	-55.92%	52W Range	3.20 - 9.69	Perf YTD	-47.17%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-23.71%	ROI	-35.27%	52W High	-68.21%	Beta	0.81
Dividend TTM	-	Quick Ratio	9.56	Sales past 5Y	230.91%	Gross Margin	50.04%	52W Low	-3.75%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	9.56	EPS Y/Y TTM	23.85%	Oper. Margin	-1276.07%	RSI (14)	28.81	Volatility	19.68% 10.41%
Employees	154	Debt/Eq	0.39	Sales Y/Y TTM	-44.71%	Profit Margin	-1188.88%	Recom	1.12	Target Price	12.14
Option/Short	No / Yes	LT Debt/Eq	0.38	EPS Q/Q	-3.84%	Payout	-	Rel Volume	8.78	Prev Close	3.33
Sales Surprise	-10.54%	EPS Surprise	20.74%	Sales Q/Q	-73.01%	Earnings	Nov 12 BMO	Avg Volume	248.63K	Price	3.08
SMA20	-29.56%	SMA50	-37.48%	SMA200	-52.29%	Trades		Volume	2,182,334	Change	-7.51%

Date	Action	Analyst	Rating Change	Price Target Change
May-16-24	Initiated	BTIG Research	Buy	$12
May-13-24	Initiated	Needham	Buy	$11
Jun-22-23	Initiated	Wedbush	Outperform	$8

Dec-09-24 05:45PM	TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) -28.23%
Dec-05-24 08:00AM	TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years (GlobeNewswire) -5.39%
Dec-02-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA Phase 1 Trial and Heme Development Strategy (GlobeNewswire)
Nov-12-24 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
04:43AM	Loading…
Nov-07-24 04:43AM	TScan Therapeutics (TCRX) Soars 7.6%: Is Further Upside Left in the Stock? (Zacks)
Nov-05-24 09:15AM	TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Oct-04-24 09:05AM	TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting (GlobeNewswire)
Aug-29-24 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-14-24 07:00AM	TScan Therapeutics Announces Updates to its Board of Directors (GlobeNewswire) -6.67%
May-30-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-29-24 07:00AM	TScan Therapeutics Receives FDA's Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies (GlobeNewswire) -6.41%
May-28-24 01:24PM	Biotech Sector Working to Combat Rising Cases of Colorectal Cancer in Young Adults (PR Newswire)
01:53PM	Loading…
May-13-24 01:53PM	TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:09AM	Janney Starts TScan Therapeutics With Buy Rating, $11 Price Target (MT Newswires)
07:00AM	TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-24 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors (GlobeNewswire)
May-01-24 10:01AM	TScan Therapeutics, Inc. (TCRX) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks) +11.66%
Apr-24-24 04:05PM	TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting (GlobeNewswire)
11:03AM	TScan Therapeutics Announces Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Apr-22-24 05:01PM	TScan Therapeutics Announces Upcoming Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting (GlobeNewswire)
Apr-19-24 10:05AM	TScan Therapeutics Announces Closing of Upsized Public Offering (GlobeNewswire)
Apr-17-24 12:30AM	TScan Therapeutics Announces Pricing of Upsized $150 Million Public Offering (GlobeNewswire) -5.33%
Apr-16-24 04:25PM	TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering (GlobeNewswire) -7.28%
04:01PM	TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities (GlobeNewswire)
Apr-08-24 08:00AM	TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer (GlobeNewswire)
Apr-02-24 07:00AM	TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire) -10.11%
02:58PM	Loading…
Mar-17-24 02:58PM	Low-Priced, High-Potential: 7 Cheap Stocks Under $10 to Try Your Luck With (InvestorPlace)
Mar-07-24 01:44PM	TScan Therapeutics Inc (TCRX) Reports Increased Revenue and Expands Clinical Pipeline (GuruFocus.com)
Mar-06-24 01:51PM	TCRX Stock Earnings: TScan Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace)
08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-28-24 07:00AM	TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Feb-26-24 07:00AM	TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-19-24 05:49AM	TScan Therapeutics, Inc. (TCRX) Stock Jumps 18.1%: Will It Continue to Soar? (Zacks)
Feb-14-24 07:00AM	TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Feb-06-24 07:00AM	TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development (GlobeNewswire) +6.67%
Jan-29-24 07:00AM	TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer (GlobeNewswire)
Jan-18-24 07:00AM	TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire) -9.62%
Jan-04-24 07:00AM	TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-09-23 12:00PM	TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire)
Dec-07-23 07:00AM	TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations (GlobeNewswire)
Dec-06-23 08:50AM	Recent Price Trend in TScan Therapeutics, Inc. (TCRX) is Your Friend, Here's Why (Zacks)
Dec-04-23 04:05PM	TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition (GlobeNewswire) -5.56% +10.46%
07:00AM	TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer (GlobeNewswire)
Dec-01-23 09:55AM	Does TScan Therapeutics, Inc. (TCRX) Have the Potential to Rally 62.33% as Wall Street Analysts Expect? (Zacks)
Nov-30-23 07:00AM	TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years (GlobeNewswire) +12.98%
Nov-27-23 12:00PM	TScan Therapeutics, Inc. (TCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
Nov-20-23 08:50AM	TScan Therapeutics, Inc. (TCRX) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks) -13.83%
Nov-15-23 12:00PM	What Makes TScan Therapeutics, Inc. (TCRX) a New Buy Stock (Zacks)
09:55AM	Wall Street Analysts Predict a 125% Upside in TScan Therapeutics, Inc. (TCRX): Here's What You Should Know (Zacks)
Nov-09-23 08:25AM	TScan Therapeutics Inc (TCRX) Reports Q3 2023 Financial Results and Corporate Updates (GuruFocus.com)
07:00AM	TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-23 07:00AM	TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting (GlobeNewswire) +11.03%
Nov-02-23 09:05AM	TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition (GlobeNewswire) +7.73%
Oct-12-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Strong Buy: Here's Why (Zacks)
Sep-27-23 09:06AM	TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-05-23 07:00AM	TScan Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-203-A0201 Targeting PRAME (GlobeNewswire) +10.96%
Aug-16-23 12:00PM	TScan Therapeutics, Inc. (TCRX) Upgraded to Buy: Here's What You Should Know (Zacks)
Aug-10-23 08:25AM	TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:00AM	TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:25AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jun-29-23 07:00AM	TScan Therapeutics Announces Transition of Chief Financial Officer (GlobeNewswire)
Jun-15-23 07:42AM	Favourable Signals For TScan Therapeutics: Numerous Insiders Acquired Stock \ (Simply Wall St.)
Jun-06-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-200-A0201 Targeting HPV16 to Treat Solid Tumors (GlobeNewswire)
Jun-01-23 04:10PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +21.65%
04:05PM	TScan Therapeutics Announces Closing of Public Offering (GlobeNewswire)
07:00AM	TScan Therapeutics to Participate in the Jefferies Healthcare Conference (GlobeNewswire)
May-26-23 12:37AM	TScan Therapeutics Announces Pricing of $140 Million Public Offering (GlobeNewswire) +31.28%
May-25-23 04:06PM	TScan Therapeutics Announces Launch of Proposed Public Offering (GlobeNewswire)
May-24-23 04:13PM	TScan Therapeutics Appoints Gavin MacBeath, Ph.D. as Chief Executive Officer and as a Member of the Board of Directors (GlobeNewswire)
May-17-23 04:35PM	TScan Therapeutics Shares Fall After Preliminary Data Highlight In Leukemia Patients (Benzinga) -10.53% -8.12%
07:00AM	TScan Therapeutics Presents Preliminary Phase 1 Clinical Results on TSC-100 and TSC-101 at the American Society of Gene & Cell Therapy 26th Annual Meeting (GlobeNewswire)
May-11-23 07:33AM	Institutional investors control 30% of TScan Therapeutics, Inc. (NASDAQ:TCRX) and were rewarded last week after stock increased 112% (Simply Wall St.) -7.22%
May-10-23 08:15AM	TScan Therapeutics, Inc. (TCRX) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +42.65%
07:00AM	TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 01:29PM	Why Are TScan Therapeutics Shares Are Shooting Higher Today (Benzinga) +51.14%
09:00AM	Amgen and TScan Therapeutics Announce Collaboration to Identify Novel Targets in Crohns Disease (GlobeNewswire)
May-02-23 04:42PM	TScan Therapeutics Announces Upcoming Trial in Progress Poster Presentation at the American Society of Gene and Cell Therapy 26th Annual Meeting (GlobeNewswire) +26.22% +10.63%
Apr-10-23 07:00AM	TScan Therapeutics Announces Appointment of Barbara Klencke, M.D., to its Board of Directors (GlobeNewswire)
Mar-31-23 08:00AM	TScan Therapeutics Announces CEO Transition (GlobeNewswire) -18.29%
Mar-14-23 07:00AM	TScan Therapeutics Announces First Patient Dosed in Phase 1 Umbrella Clinical Trial Evaluating TSC-100 and TSC-101 for the Treatment of Hematologic Malignancies (GlobeNewswire)
Mar-13-23 04:05PM	TScan Therapeutics to Participate in the Barclays Global Healthcare Conference (GlobeNewswire) -13.31%
Mar-10-23 05:12AM	TScan Therapeutics Full Year 2022 Earnings: Misses Expectations (Simply Wall St.)
Mar-08-23 07:00AM	TScan Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Upcoming Milestones (GlobeNewswire)
Mar-01-23 07:00AM	TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference (GlobeNewswire) +6.78%
Feb-21-23 07:00AM	TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference (GlobeNewswire)
Jan-23-23 07:00AM	TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors (GlobeNewswire)
Jan-20-23 05:35AM	Shareholders in TScan Therapeutics (NASDAQ:TCRX) are in the red if they invested a year ago (Simply Wall St.)
Jan-05-23 07:00AM	TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress (GlobeNewswire)
Dec-12-22 07:00AM	TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022 (GlobeNewswire)
Dec-09-22 06:09AM	A number of insiders bought TScan Therapeutics, Inc. (NASDAQ:TCRX) stock last year, which is great news for shareholders (Simply Wall St.)
Dec-01-22 08:00AM	TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe (GlobeNewswire)
Nov-22-22 07:00AM	TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference (GlobeNewswire)
Nov-11-22 07:00AM	TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +7.81%

TScan Therapeutics, Inc. discovers and develops transformative T cell therapies (TCR-T) to treat liquid cancers, solid tumors and other serious diseases. Its platform identifies previously uncharacterized, clinically-derived shared T cell antigens and all off-target TCR interactions, to enable the development of efficacious TCR-Ts. The company was founded by Christoph H. Westphal, Stephen Elledge, Lea Hachigian, and Tomasz Kula in 2018 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lynx1 Capital Management LP	10% Owner	Nov 15 '24	Buy	4.34	947	4,114	5,225,547	Nov 19 04:26 PM
Klencke Barbara	Director	Sep 23 '24	Buy	5.29	5,000	26,450	45,000	Sep 24 05:26 PM
Klencke Barbara	Director	Aug 23 '24	Buy	5.69	5,000	28,450	35,000	Aug 27 06:57 PM
Klencke Barbara	Director	Aug 26 '24	Buy	5.53	5,000	27,650	40,000	Aug 27 06:57 PM
ZDRAVESKI ZORAN	See Remarks	Aug 23 '24	Option Exercise	3.38	157,186	531,520	169,402	Aug 27 06:46 PM
ZDRAVESKI ZORAN	See Remarks	Aug 23 '24	Sale	5.78	164,686	952,116	4,716	Aug 27 06:46 PM
ZDRAVESKI ZORAN	Officer	Aug 23 '24	Proposed Sale	5.50	164,686	905,773		Aug 23 05:50 PM
BARBERICH TIMOTHY J	Director	Dec 18 '23	Buy	4.89	28,830	140,881	66,710	Dec 21 05:00 PM
BARBERICH TIMOTHY J	Director	Dec 19 '23	Buy	4.97	317	1,575	67,027	Dec 21 05:00 PM
Klencke Barbara	Director	Dec 14 '23	Buy	5.08	5,000	25,400	30,000	Dec 18 06:01 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRX

Tscan Therapeutics Inc

Upgrade your FINVIZ experience